Increased total and high-molecular weight adiponectin after extended-release niacin

Metabolism: Clinical and Experimental

Volumn 57, Issue 3, 2008, Pages 404-409

  Plaisance, Eric P ^a   Grandjean, Peter W ^a   Brunson, Brandon L ^a   Judd, Robert L ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADIPONECTIN; NICOTINIC ACID;

ADULT; ARTICLE; BODY COMPOSITION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; MOLECULAR WEIGHT; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ADIPONECTIN; ADULT; ANTILIPEMIC AGENTS; BODY COMPOSITION; BODY WEIGHT; CARDIOVASCULAR DISEASES; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MOLECULAR WEIGHT; NIACIN;

EID: 38749110451     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2007.10.018     Document Type: Article

References (32)

1. James P.T., Leach R., Kalamara E., et al. The worldwide obesity epidemic. Obes Res 9 Suppl 4 (2001) 228S-233S
2. NCEP. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2496
3. Goldberg A., Alagona P., Capuzzi D.M., et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 85 (2000) 1100-1105
4. Grundy S., Vega G.L., McGovern M.E., et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial. Arch Int Med 162 (2002) 1568-1576
5. Guyton J., Goldberg A.C., Kreisberg R.A., et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 82 (1998) 737-743
6. Tunaru S., Kero J., Schaub A., et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 9 (2003) 352-355
7. Zhang Y., Schmidt R.J., Foxworthy P., et al. Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A. Biochem Biophys Res Commun 334 (2005) 729-732
8. Ungerstedt J.S., Blomback M., and Soderstrom T. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol 131 (2003) 48-52
9. Westphal S., Borucki K., and Taneva E. Extended-release niacin raises adiponectin and leptin. Atherosclerosis (2006) In Press
10. Arita Y., Kihara S., Ouchi N., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 (1999) 79-83
11. Scherer P.E., Williams S., Fogliano M., et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270 (1995) 26746-26749
12. Waki H., Yamauchi T., Kamon J., et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 278 (2003) 40352-40363
13. Pajvani U.B., Hawkins M., Combs T.P., et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279 (2004) 12152-12162
14. Berg A.H., Combs T.P., and Scherer P.E. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 13 (2002) 84-89
15. Lin C.Y., Higginbotham D.A., Judd R.L., et al. Central leptin increases insulin sensitivity in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab 282 (2002) E1084-E1091
16. Chandran M.J., Phillips S.A., Ciaraldi T., et al. Adiponectin: more than just another fat cell hormone. Diabetes Care 26 (2003) 2442-2450
17. Wang W., Basinger A., Neese R.A., et al. Effects of nicotinic acid on fatty acid kinetics, fuel selection, and pathways of glucose production in women. Am J Physiol Endocrinol Metab 279 (2000) E50-E59
18. Vega G.L., Cater N.B., Meguro S., et al. Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia. Am J Cardiol 95 (2005) 1309-1313
19. Blackburn P., Lamarche B., Couillard C., et al. Postprandial hyperlipidemia: another correlate of the "hypertriglyceridemic waist" phenotype in men. Atherosclerosis 171 (2003) 327-336
20. Capuzzi D., Guyton J.R., Morgan J.M., et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 82 (1998) 74U-81U
21. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 231 (1975) 360-381
22. Wang-Fisher Y.L., Han J., and Guo W. Acipimox stimulates leptin production from isolated rat adipocytes. J Endocrinol 174 (2002) 267-272
23. Weyer C., Funahashi T., Tanaka S., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86 (2001) 1930-1935
24. Berg A.H., and Scherer P.E. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96 (2005) 939-949
25. Trujillo M.E., and Scherer P.E. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Int Med 257 (2005) 167-175
26. Yamauchi T., Kamon J., Minokoshi Y., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8 (2002) 1288-1295
27. Ouchi N., Kihara S., Arita Y., et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100 (1999) 2473-2476
28. Arita Y., Kihara S., Ouchi N., et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105 (2002) 2893-2898
29. Westphal S., Borucki K., Taneva E., et al. Adipokines and treatment with niacin. Metabolism 55 (2006) 1283-1285
30. Heliovaara M.K., Strandberg T.E., Karonen S.L., et al. Association of serum adiponectin concentration to lipid and glucose metabolism in healthy humans. Horm Metab Res 38 (2006) 336-340
31. Serlie M.J., Allick G., Groener J.E., et al. Chronic treatment with pioglitazone does not protect obese patients with diabetes mellitus type II from free fatty acid-induced insulin resistance. J Clin Endocrinol Metab 92 (2007) 166-171
32. Zhao S., Yang J., Li J., et al. Effect of niacin on LXRalpha and PPARgamma expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits. Int J Cardiol (2007) [in press]